Center for Tobacco Products

The Food and Drug Administration, a sub-agency of the Department of Health and Human Services, administers federal grants in support of regulatory science, product standards harmonization, public health research, and tobacco control initiatives. The FDA grants modest sums across a highly fragmented recipient base focused on standards development, nicotine research, and clinical data standardization.

The FDA has obligated $471.7 million in federal grant funding across 163 awards since 2013, distributed among 86 distinct recipients. Recent grant activity has slowed significantly: the agency issued 2 awards in 2022, 3 in 2023, 4 in 2024, 1 in 2025, and 1 so far in 2026, with the most recent award dated March 2026. Grant assistance splits predominantly toward Project Grants (109 awards, 67 percent) with a substantial Cooperative Agreement share (54 awards, 33 percent).

Recent grant recipients are highly fragmented by federal dollars. The Society For Research On Nicotine & Tobacco Inc. leads by award count with 5 grants totaling $350 thousand in federal dollars obligated over the last five years, followed by Clinical Data Interchange Standards Consortium Inc. and University of Missouri System at 2 awards each ($3 million and $650 thousand respectively). The top five recipients account for only 1 percent of recent federal grant dollars, reflecting a grant portfolio distributed across small to moderate awards to academic institutions, nonprofit research organizations, and international bodies such as the World Health Organization. No single recipient has captured material share of recent FDA grant funding.

The compressed award cadence in 2025 and 2026 signals either a pullback in FDA grant-making activity, a shift in funding cycles, or a concentration of award activity into periods not yet reflected in the digest. Business development professionals should monitor whether the agency returns to prior-year issuance levels (2–4 awards annually) or sustains the current reduced pace. The dominance of Project Grants over Cooperative Agreements indicates preference for time-limited research support rather than long-term joint ventures; recipients should expect fixed-period, defined-scope arrangements with modest federal shares.